The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis
Academic Article
Overview
MeSH Major
Antirheumatic Agents
Arthritis, Rheumatoid
Methotrexate
abstract
Initial treatment with subcutaneous MTX was associated with lower rates of treatment changes, no difference in toxicity and some improvements in disease control versus oral MTX over the first year in patients with ERA.
